Sergio Cifuentes Canaval, Medical Oncologist at Las Américas Auna Clinic, shared a post on X about a paper by Peter A. Fasching et al. published in JAMA Oncology:
”First ESMO25 papers are starting to emerge!
One of the most anticipated: Ribociclib + endocrine therapy in early HR+/HER2- breast cancer.
4-year results from the NATALEE.”
Title: Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ERBB2-Negative Early Breast Cancer4-Year Outcomes From the NATALEE Randomized Clinical Trial
Authors: Peter A. Fasching, Daniil Stroyakovskiy, Denise A. Yardley, Chiun-Sheng Huang, John Crown, Aditya Bardia, Stephen Chia, Seock-Ah Im, Miguel Martin, Binghe Xu, Sherene Loi, Carlos Barrios, Michael Untch, Rebecca Moroose, Frances Visco, Gabriel N. Hortobagyi, Dennis J. Slamon, Rodrigo Fresco, Juan Pablo Zarate, Zheng Li, Sorcha Waters, Sara A. Hurvitz
You can read the Full Article on JAMA Oncology.
More from Sergio Cifuentes Canaval on OncoDaily.